Art. 28a Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 2 Jul 2012cited 3×
1.

Regarding medicinal products for human use authorised in accordance with this Regulation, the Agency shall, in collaboration with the Member States, take the following measures:

(a)

monitor the outcome of risk minimisation measures contained in risk management plans and of conditions referred to in points (c), (ca), (cb) and (cc) of Article 9(4) or in points (a) and (b) of Article 10a(1), and in Article 14(7) and (8);

(b)

assess updates to the risk management system;

(c)

monitor the data in the Eudravigilance database to determine whether there are new risks or whether risks have changed and whether those risks impact on the risk-benefit balance.

2.

The Pharmacovigilance Risk Assessment Committee shall perform the initial analysis and prioritisation of signals of new risks or risks that have changed or changes to the risk-benefit balance. Where it considers that follow-up action may be necessary, the assessment of those signals and agreement on any subsequent action concerning the marketing authorisation shall be conducted in a timescale commensurate with the extent and seriousness of the issue.

3.

The Agency and national competent authorities and the marketing authorisation holder shall inform each other in the event of new risks or risks that have changed or changes to the risk-benefit balance being detected.

  • Commission Implementing Regulation (EU) No 520/2012 of 19 June 2012 on the performance o…21Law

    … 2, i direktiv 2001/83/EF og artikel 28a, stk. 2, i forordning (EF) nr. 726/2004. 6. Agenturet underretter straks den eller de berørte indehavere af markedsføringstilladelsen om de konklusioner, som Udvalget for Risikovurdering inden for …

  • Judgment of the Court (Third Chamber) of 25 November 2021. Delfarma Sp. z o.o. v Prezes Urzędu Rejestracji Produktów Leczniczych, Wyrobów MeDecision

    Article 28a(3) of that regulation reads as follows: The [EMA] and national competent authorities and the marketing authorisation holder shall inform each other in the event of new risks or risks that have changed or changes to the …

    25 Nov 2021 · 62020CJ0488

  • Commission Implementing Regulation (EU) No 520/2012 of 19 June 2012 on the performance o…21Law

    … for the initial analysis and prioritisation of signals in accordance with Article 107h(2) of Directive 2001/83/EC and Article 28a(2) of Regulation (EC) No 726/2004. 6. The Agency shall inform forthwith the marketing authorisation holder(s) …